Evidence map›Paper›PMID 37867243›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023

Tumor Microenvironment Responsive CD8

Qiangda Chen, Hanlin Yin, Junyi He, Yuqi Xie, Wenquan Wang, Huaxiang Xu, Lei Zhang, Chenye Shi, Jun Yu, Wenchuan Wu and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. CD73Frontiers in medicine · 2025
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Qiangda ChenDepartment of Pancreatic Surgery, Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Hanlin YinDepartment of Pancreatic Surgery, Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Junyi HeDepartment of Pancreatic Surgery, Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Yuqi XieDepartment of Pancreatic Surgery, Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Wenquan WangDepartment of Pancreatic Surgery, Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Huaxiang XuDepartment of Pancreatic Surgery, Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Lei ZhangDepartment of Pancreatic Surgery, Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Chenye ShiDepartment of Pancreatic Surgery, Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Jun YuDepartments of Medicine and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Wenchuan WuDepartment of Pancreatic Surgery, Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Liang LiuDepartment of Pancreatic Surgery, Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Ning PuDepartment of Pancreatic Surgery, Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.ORCID 0000-0002-3123-493X
Wenhui LouDepartment of Pancreatic Surgery, Cancer Center, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Fudan University · CNJohns Hopkins University · US

Funding

China Postdoctoral Science Foundation 2021M690037National Natural Science Foundation of China 81827807National Natural Science Foundation of China 81972218National Natural Science Foundation of China 81972257National Natural Science Foundation of China 82103409National Natural Science Foundation of China 82173116National Natural Science Foundation of China 82272929National Natural Science Foundation of China 82273382Shanghai Municipal Health Commission 20224Y0307Shanghai Sailing Program 21YF1407100Shanghai ShenKang Hospital Development Centre Project SHDC2020CR2017B
6 · The paper itself

Abstract

CD73 plays a critical role in the pathogenesis and immune escape in pancreatic ductal adenocarcinoma (PDAC). AB680, an exceptionally potent and selective inhibitor of CD73, is administered in an early clinical trial, in conjunction with gemcitabine and anti-PD-1 therapy, for the treatment of PDAC. Nevertheless, the specific therapeutic efficacy and immunoregulation within the microenvironment of AB680 monotherapy in PDAC have yet to be fully elucidated. In this study, AB680 exhibits a significant effect in augmenting the infiltration of responsive CD8

Indexed as

Carcinoma, Pancreatic DuctalMyeloid-Derived Suppressor CellsPancreatic NeoplasmsAnimalsCD8-Positive T-LymphocytesGemcitabineMicePyrazolesTumor MicroenvironmentGemcitabinePyrazolesquemliclustatAB680CD73combination therapypancreatic cancer

Identifiers

PMID37867243
PMCPMC10667825
OpenAlexW4387866247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.